Global Ebola Virus Vaccine Market - 2025-2033

The global ebola virus vaccine market reached US$ 173.82 million in 2024 and is expected to reach US$ 288.41 million by 2033, growing at a CAGR of 6.4 % during the forecast period 2025-2033.

Ebola vaccines are designed to prevent ebola virus disease (EVD), a severe and often fatal hemorrhagic fever. These vaccines work by stimulating the immune system to recognize and fight the ebola virus. Protection is achieved through various methods, such as using a weakened virus, viral vectors, or genetic material. The goal is to protect those at high risk of exposure, including healthcare workers and outbreak response teams.

The ebola virus vaccine market involves all activities related to creating, manufacturing, distributing, and giving vaccines that protect against ebola. These vaccines are essential for controlling outbreaks and stopping the disease from spreading, especially in regions where ebola is common or where outbreaks have happened in the past. These factors have driven the global ebola virus vaccine market expansion.

Rising Incidence of Ebola

The rising incidence of ebola is significantly driving the growth of the global ebola virus vaccine market and is expected to drive throughout the market forecast period. In recent decades, there have been several significant Ebola outbreaks, mainly in West and Central Africa. As the virus resurfaces periodically, the demand for vaccines increases to address these urgent situations. The growing frequency of outbreaks heightens awareness and creates a sense of urgency, driving the need for effective vaccination programs to prevent further spread of the virus.

Vaccines designed to protect against certain strains of Ebola have been utilized to help contain the spread of the virus during outbreaks. Additional vaccines are still under development. Early supportive treatment, such as rehydration and symptom management, has been shown to improve survival rates.

According to the World Health Organization (WHO) data in August 2023, strongly recommends two monoclonal antibody treatments for Ebola: mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb), both of which have proven effective in treating the disease. On average, the fatality rate for Ebola is about 50%, though it has ranged from 25% to 90% in past outbreaks, depending on the specific circumstances and response efforts.

Effective outbreak control requires a combination of actions, including patient care, infection prevention and control, disease surveillance, contact tracing, reliable laboratory services, safe and respectful burials, and social mobilization. Community engagement is crucial for the successful management and containment of Ebola outbreaks. All these factors demand the global ebola virus vaccine market.

Furthermore, key players in the industry more focus on research activities that would propel the global ebola virus vaccine market growth. For instance, in July 2024, the Sabin Vaccine Institute initiated a Phase 2 clinical trial in Uganda for its single-dose vaccine targeting the Sudan ebolavirus strain, for which there are currently no approved vaccines. Healthy volunteers are participating in the trial at the Makerere University Walter Reed Project (MUWRP).

Also, in March 2023, AIM ImmunoTech Inc. is exploring Ampligen (rintatolimod) as a potential early-onset prophylactic therapy against human Ebola outbreaks. New research supports Ampligen's ability to inhibit the spread and replication of Ebola virus disease. This adds to the evidence of its potential use against Ebola. Ampligen is a broad-spectrum immuno-modulator. It is under evaluation for treating various cancers, viral diseases, and immune system disorders. In a mouse model, Ampligen demonstrated 100% prophylactic protection against Ebola at easily achievable human doses. Moreover, the rising demand for the expanding immunization programs contributes to the global ebola virus vaccine market expansion.

Stringent Regulatory Approval

The stringent regulatory approval process is a major restraint in the global Ebola virus vaccine market. This challenge arises from the thorough, complex, and often lengthy procedures that ensure the safety, efficacy, and quality of vaccines before they are approved for widespread use.

Vaccines go through several stages of clinical testing to ensure they are both safe and effective. These stages include preclinical studies, Phase 1 (small safety trials), Phase 2 (testing efficacy and safety in a larger group), and Phase 3 (large-scale trials to confirm efficacy). Each phase requires careful data collection and analysis, which can take several years to complete. The extended timeline for clinical trials can delay the market entry of Ebola vaccines, raising development costs. These delays are particularly concerning during outbreaks, as they limit the availability of vaccines when they are urgently needed to control the virus.

After completing clinical trials, vaccines must undergo a thorough review by regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the World Health Organization (WHO). These bodies assess whether the vaccine meets safety, efficacy, and manufacturing standards. During Ebola outbreaks, some regulatory agencies grant Emergency Use Authorizations (EUAs) or accelerated approvals to fast-track vaccine access. However, even these expedited processes involve regulatory scrutiny and additional steps to ensure the vaccine is safe and effective under emergency conditions. Thus, the above factors could be limiting the global ebola virus vaccine market's potential growth.

Segment Analysis

The global ebola virus vaccine market is segmented based on strain type, vaccine type, end-user, and region.

Strain Type:

The zaire ebolavirus segment is expected to dominate the global ebola virus vaccine market share

The Zaire ebolavirus segment holds a major portion of the global ebola virus vaccine market share and is expected to continue to hold a significant portion of the global ebola virus vaccine market share during the forecast period.

Zaire ebolavirus is one of the five species of the Ebola virus and is recognized as the most lethal, responsible for the majority of Ebola outbreaks globally. This strain causes hemorrhagic fever in humans and non-human primates, with a high fatality rate, often exceeding 50%. First identified during the 1976 Ebola outbreak in Zaire the virus was named after the region.

Zaire ebolavirus is responsible for the majority of large Ebola outbreaks, especially in regions like the Democratic Republic of the Congo, Guinea, and Sierra Leone. The recurring nature of these outbreaks increases the need for vaccines. International organizations like the WHO support ongoing vaccine development, including efforts to stockpile vaccines for future outbreaks, ensuring that vaccines are ready for deployment when outbreaks occur.

Vaccine developers are intensifying their focus on improving vaccines for Zaire ebolavirus due to the virus’s high fatality rate. The goal is not only to enhance vaccine efficacy but also to make them more accessible, especially in low-resource areas where outbreaks are most common. Researchers are working on developing combination vaccines that could offer protection against multiple strains of Ebola, such as Zaire ebolavirus and Sudan virus. This would expand the vaccine's use and make it more versatile in outbreak control.

Furthermore, key players in the industry strategies such as partnerships and collaborations that would drive this global ebola virus vaccine market growth. For instance, in February 2025, Uganda, in collaboration with the World Health Organization (WHO) and other global partners, may consider launching a clinical trial for a vaccine against the Zaire ebolavirus following a recent outbreak. While licensed vaccines exist for the Zaire ebolavirus, further trials could play a pivotal role in controlling future outbreaks and pave the way for regulatory approval for additional vaccines.

The efficacy of ring trials has been established in studies that evaluated trials of MSD’s rVSV vaccine Ervebo, which was investigated in the Zaire Ebola outbreak in the Democratic Republic of Congo. These factors have solidified the segment's position in the global ebola virus vaccine market.

Geographical Analysis

North America is expected to hold a significant position in the global ebola virus vaccine market share

North America holds a substantial position in the global ebola virus vaccine market and is expected to hold most of the market share.

The North American ebola virus vaccine market plays an essential role in the global response to Ebola outbreaks, particularly when it comes to research, development, and preparedness. While the region has not been directly affected by large-scale Ebola outbreaks, its advanced healthcare infrastructure, research efforts, and funding mechanisms significantly contribute to vaccine development and deployment. North America remains a key player in both vaccine innovation and global health leadership.

The U.S. government, through agencies like the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), has been instrumental in financing the development of Ebola vaccines. These agencies fund research, clinical trials, and preparedness initiatives. Additionally, the U.S. government has supported global health initiatives aimed at combating Ebola outbreaks through the U.S. Agency for International Development (USAID) and collaborations with international bodies like the World Health Organization (WHO).

North America hosts leading pharmaceutical companies and research institutions dedicated to developing Ebola vaccines, such as Merck & Co., Johnson & Johnson, and Moderna. These companies have pioneered vaccines like Ervebo (V920) and continue to explore new vaccine formulations targeting various Ebola strains and even combination vaccines.

For instance, in August 2023, the U.S. Food and Drug Administration (FDA) expanded the approved use of Merck's ERVEBO vaccine to include children as young as 12 months old. ERVEBO is now indicated for the prevention of disease caused by the Zaire ebolavirus in individuals 12 months of age and older. Previously, it was only approved for those 18 years and older.

Also, in November 2022, AIM ImmunoTech Inc. received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its drug Ampligen (rintatolimod) as a treatment for Ebola virus disease. Ampligen, an immuno-modulator with broad-spectrum activity, is being investigated for cancers, viral diseases, and immune disorders. While Ebola is not AIM's primary focus, this designation provides further validation and potential future options for the company. Ampligen has shown promise in animal studies for treating Ebola. Thus, the above factors are consolidating the region's position as a dominant force in the global ebola virus vaccine market.

Asia Pacific is growing at the fastest pace in the global ebola virus vaccine market share

Asia Pacific holds the fastest pace in the global ebola virus vaccine market and is expected to hold most of the market share. The growing number of Ebola outbreaks in West and Central Africa has increased awareness among APAC nations about the risks of infectious diseases, including Ebola. As a result, there is a heightened focus on preparedness and the development of vaccines to protect against emerging health threats. The increasing volume of international travel and trade makes the spread of diseases like Ebola more likely. APAC countries are prioritizing pandemic preparedness to prevent the virus from crossing borders, which includes investing in vaccine stockpiles and development initiatives.

APAC countries are actively collaborating with global health organizations and other governments to address health emergencies. Key organizations like the World Health Organization (WHO), the Global Health Security Agenda (GHSA), and the Bill & Melinda Gates Foundation are instrumental in supporting the region with funding, research, and distribution of Ebola vaccines. Countries across the APAC region are joining forces to strengthen healthcare systems and improve their ability to respond to health emergencies. These collaborations enhance access to vaccines and improve distribution capabilities within the region.

The APAC region is home to a rapidly growing pharmaceutical and biotechnology sector. Many of these companies are focusing on the development of vaccines for infectious diseases, including Ebola. Nations such as India, China, and Singapore are major players in vaccine manufacturing and are increasingly contributing to global vaccine production.

For instance, in December 2022, the Serum Institute of India (SII) manufactured and dispatched 40,000 doses of Oxford's Ebola vaccine to Uganda in response to the Sudan ebolavirus outbreak declared by the World Health Organization (WHO). The doses were shipped within 80 days of the declaration.

Also, in May 2024, RedHill Biopharma announced that it received a new Chinese patent for opaganib as a therapy for inhibiting single-stranded RNA virus replication, including the Ebola virus. The patent, which is valid until 2035, strengthens the company's intellectual property portfolio.

Opaganib is currently being developed for multiple conditions, including COVID-19, acute respiratory distress syndrome, and government-sponsored countermeasures for Acute Radiation Syndrome and Sulfur Mustard exposure. Studies suggest opaganib may be the first host-directed molecule to increase survival in Ebola virus disease. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global ebola virus vaccine market.

Competitive Landscape

The major global players in the ebola virus vaccine market include Johnson & Johnson, Merck & Co., Inc., GSK plc., CansinoBl0, and AIM ImmunoTech Inc. among others.

Key Developments
• In June 2024, Gavi, the Vaccine Alliance, announced the launch of programs to introduce four additional vaccines in countries it supports: preventive Ebola, human rabies (for post-exposure prophylaxis), multivalent meningococcal conjugate, and hepatitis B birth dose. These programs, previously approved by the Gavi Board, had been put on hold due to the recent pandemic.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global ebola virus vaccine market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.